# An Open-label Study That Will Test a Second Treatment Session of RZL-012.

> **NCT05763160** · PHASE2 · COMPLETED · sponsor: **Raziel Therapeutics Ltd.** · enrollment: 15 (actual)

## Conditions studied

- Submental Fat

## Interventions

- **DRUG:** RZL-012

## Key facts

- **NCT ID:** NCT05763160
- **Lead sponsor:** Raziel Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-29
- **Primary completion:** 2023-07-30
- **Final completion:** 2023-10-20
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05763160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05763160, "An Open-label Study That Will Test a Second Treatment Session of RZL-012.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05763160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*